Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting

MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that detailed results from the Phase 2 HELP Study of levosimendan in PH-HFpEF will be presented at the upcoming Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting to be held September 30, – October 6. Scheduling details and registration information are provided below:

Title:

 

Levosimendan Improves Hemodynamics and Submaximal Exercise Capacity In PH-HFpEF: Primary Results From The HELP-PH-HFpEF Multicenter Randomized Controlled Trial

 

 

Speaker:

 

Dr. Barry Borlaug, Chair for Research, Division of Circulatory Failure, Department of Cardiovascular Medicine at the Mayo Clinic

 

 

Session:

 

Late-Breaking Clinical Trials I (LBCT I)

 

 

Date/Time:

 

Saturday, October 3, 4:30 – 5:30 PM

   

Registration and additional HFSA information are available at the HFSA website: https://hfsa.org/hfsa-announces-late-breaking-clinical-trials-sessions-hfsa-virtual-asm-2020.

Tenax CEO Anthony DiTonno stated, “We are very excited to have the HELP

Read More